today announced the initiation of the EMBO-02 clinical study of NeoCast™ to treat chronic subdural hematomas (cSDH). NeoCast is a first-of-its-kind, shear-responsive, non-adhesive, solvent-free, ...
The predominant treatment for prostate cancer, a prevalent malignancy in men, is the surgical removal of the prostate (radical prostatectomy) for which biopsy is a prerequisite. However, the high ...
Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...
Hospitals are already deploying artificial intelligence (AI) to enhance patient care. But can it actually improve doctors' diagnoses? A new study has surprising answers.